stars 1 stars 2 stars 3

Genosco is a clinical-stage biotech pursuing discovery and development of novel small-molecule drugs for patients with unmet medical needs. Our proprietary G-SMART™ platform enables discovery and optimization based on rare sequences in protein kinases that can be targeted to develop a highly selective compound. This innovative approach has enabled us to build a strong portfolio of multiple independent and partnered pipelines. Our most advanced pipeline, Lazertinib, is currently undergoing phase 3 global clinical trial by Janssen and is also available in Korea for patients with EGFRm+ non-small cell lung cancer. Robust research and discovery programs are also underway. With a shared mission to enhance people’s lives through innovative science, we are united in developing world-class precision medicine to help people have healthier and longer lives. Our interdisciplinary team consists of scientists with deep expertise in medicinal chemistry, structural & computational drug discovery design, cell biology, pharmacology, and drug metabolism.

Genosco Questions

The Genosco annual revenue was $9 million in 2026.

Yong Yang is the cfo of Genosco.

19 people are employed at Genosco.

Genosco is based in Billerica, Massachusetts.

The NAICS codes for Genosco are [325, 32, 32541, 3254].

The SIC codes for Genosco are [283, 28].

Top Genosco Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users